Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 37Carboplatin 26Radiotherapy 23Cisplatin 19Paclitaxel 18Erlotinib Hydrochloride 18Docetaxel 15Gemcitabine 14Pemetrexed 13Etoposide 12osimertinib 11Nivolumab 11durvalumab 9atezolizumab 9Radiosurgery 8Magnetic Resonance Spectroscopy 8Cetuximab 7Specimen Handling 6Cyclophosphamide 6130-nm albumin-bound paclitaxel 6Taxes 5Immunoglobulin G 5Gefitinib 5Biopsy 5Bevacizumab 5fludarabine 4Radiation 4Ipilimumab 4Disulfides 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Lung Neoplasms × Pharmacogenomic Variants × Clear all
NCT03582124 2026-02-10

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Stanford University

Phase 1/2 Recruiting
30 enrolled
Thoracic

Lung Neoplasms

NCT03225664 2026-01-16

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
37 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡